Nonconvulsive status epilepticus characteristics in glioma patients: a retrospective study

Kaneoka, Azumi; Ikeda, Akio; Tamura, Kaoru; Inaji, Motoki; Maehara, Taketoshi

doi:10.1007/s12672-023-00632-3

Cited by 1 publication

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A limited number of studies have focused on this specific patient group, and the majority of these were retrospective, involved only a single center, and consisted of small patient cohorts. Our literature review identified seven original studies [ 14 , 16 , 33 – 37 ] and two reviews [ 9 , 15 ], the details of which are presented in Table 4 . These studies indicated that SE patients with brain tumors averaged 55–68 years of age and mainly included males.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Status epilepticus in patients with brain tumors and metastases: A multicenter cohort study of 208 patients and literature review

Rickel,

Zeeb,

Knake

et al. 2024

Neurol. Res. Pract.

View full text Add to dashboard Cite

Objective Brain tumors and metastases account for approximately 10% of all status epilepticus (SE) cases. This study described the clinical characteristics, treatment, and short- and long-term outcomes of this population. Methods This retrospective, multi-center cohort study analyzed all brain tumor patients treated for SE at the university hospitals of Frankfurt and Marburg between 2011 and 2017. Results The 208 patients (mean 61.5 ± 14.7 years of age; 51% male) presented with adult-type diffuse gliomas (55.8%), metastatic entities (25.5%), intracranial extradural tumors (14.4%), or other tumors (4.3%). The radiological criteria for tumor progression were evidenced in 128 (61.5%) patients, while 57 (27.4%) were newly diagnosed with tumor at admission and 113 (54.3%) had refractory SE. The mean hospital length of stay (LOS) was 14.8 days (median 12.0, range 1–57), 171 (82.2%) patients required intensive care (mean LOS 8.9 days, median 5, range 1–46), and 44 (21.2%) were administered mechanical ventilation. All patients exhibited significant functional status decline (modified Rankin Scale) post-SE at discharge (p < 0.001). Mortality at discharge was 17.3% (n = 36), with the greatest occurring in patients with metastatic disease (26.4%, p = 0.031) and those that met the radiological criteria for tumor progression (25%, p < 0.001). Long-term mortality at one year (65.9%) was highest in those diagnosed with adult-type diffuse gliomas (68.1%) and metastatic disease (79.2%). Refractory status epilepticus cases showed lower survival rates than non-refractory SE patients (log-rank p = 0.02) and those with signs of tumor progression (log-rank p = 0.001). Conclusions SE occurrence contributed to a decline in functional status in all cases, regardless of tumor type, tumor progression status, and SE refractoriness, while long-term mortality was increased in those with malignant tumor entities, tumor progressions, and refractory SE. SE prevention may preserve functional status and improve survival in individuals with brain tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Previous studies have reported tumor-associated SE refractoriness ranging from 12 to 57.9% [ 9 , 14 – 16 , 33 – 37 ]. Reviews have indicated that TASE tends to be more responsive than SE to first- and second-line ASMs in the general population, with refractoriness evident in only 12–18% of cases [ 9 ].…”

Section: Discussionmentioning

confidence: 99%